Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Report – Research, Industry Analysis Reports and Market Demands

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 5-HT3 Inhibitors
- 1.3.3 NK1 Inhibitors
- 1.3.4 Other
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Acute CINV
- 1.4.3 Delayed CINV
- 1.4.4 Breakthrough CINV
- 1.4.5 Others
1.5 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size & Forecast
- 1.5.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity (2021-2032)
- 1.5.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Chemotherapy Induced Nausea and Vomiting (CINV) Drugs by Manufacturer

3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue by Manufacturer (2021-2026)
3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Manufacturer Market Share in 2025
- 3.4.3 Top 6 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Manufacturer Market Share in 2025
3.5 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Overall Company Footprint Analysis
- 3.5.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Region Footprint
- 3.5.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Company Product Type Footprint
- 3.5.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size by Region
- 4.1.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Region (2021-2032)
- 4.1.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Region (2021-2032)
- 4.1.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Average Price by Region (2021-2032)
4.2 North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value (2021-2032)
4.3 Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value (2021-2032)
4.5 South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Type (2021-2032)
5.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Type (2021-2032)
5.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Application (2021-2032)
6.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Application (2021-2032)
6.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Average Price by Application (2021-2032)

7 North America

7.1 North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Type (2021-2032)
7.2 North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Application (2021-2032)
7.3 North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size by Country
- 7.3.1 North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Country (2021-2032)
- 7.3.2 North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Type (2021-2032)
8.2 Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Application (2021-2032)
8.3 Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size by Country
- 8.3.1 Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size by Region
- 9.3.1 Asia-Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Type (2021-2032)
10.2 South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Application (2021-2032)
10.3 South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size by Country
- 10.3.1 South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Country (2021-2032)
- 10.3.2 South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size by Country
- 11.3.1 Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Drivers
12.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Restraints
12.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs
13.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Typical Distributors
14.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size was valued at US$ 2298 million in 2025 and is forecast to a readjusted size of US$ 2055 million by 2032 with a CAGR of -1.6% during review period.
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
The market for Chemotherapy Induced Nausea and Vomiting (CINV) drugs is primarily driven by the rising global cancer burden and the growing use of aggressive chemotherapy regimens. As cancer treatments become more potent, side effects like nausea and vomiting become more frequent and severe, increasing the demand for effective antiemetic therapies. The availability of combination antiemetic drugs, such as NK1 receptor antagonists, 5-HT3 antagonists, and corticosteroids, has significantly improved patient outcomes and quality of life. Furthermore, increasing awareness among patients and oncologists about the importance of supportive care is encouraging the adoption of CINV drugs in both inpatient and outpatient settings.
Despite the growth potential, the CINV drugs market faces several challenges. One of the primary hurdles is the high cost of novel antiemetic therapies, which limits access in low- and middle-income countries. Generic competition is also impacting the revenues of branded products. Additionally, not all patients respond equally to antiemetic drugs, and some experience breakthrough or refractory nausea despite prophylactic treatment. These clinical limitations highlight the need for personalized therapy, but variability in patient responses makes it difficult to standardize treatment protocols. Regulatory hurdles and slow drug approval timelines further restrain market expansion.
A key trend in the CINV drugs market is the development of long-acting and combination therapies that improve adherence and efficacy. Innovations like extended-release formulations and transdermal delivery systems are gaining popularity for their convenience and effectiveness. There's also a growing focus on integrating CINV drugs into broader oncology care programs, including palliative and home-based care. Pharmaceutical companies are investing in clinical trials to expand the indications of existing antiemetics and explore novel targets such as cannabinoid receptors. As cancer care becomes more patient-centric, the demand for well-tolerated and accessible CINV treatments is expected to grow steadily.
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top five manufacturers hold a share over 26%.
This report is a detailed and comprehensive analysis for global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Chemotherapy Induced Nausea and Vomiting (CINV) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche, Viatris, Baxter, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Market segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
Major players covered
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Viatris
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs, with price, sales quantity, revenue, and global market share of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs from 2021 to 2026.
Chapter 3, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs.
Chapter 14 and 15, to describe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs sales channel, distributors, customers, research findings and conclusion.

Buy now